![Syringe with Fusion logo on it](https://investinhamilton.ca/wp-content/uploads/2018/11/hamilton-fusion-555x375.gif)
Fusion Pharmaceuticals Raises $105 Million In Oversubscribed Series B Financing
Lead investors Varian and OrbiMed, are joined by Perceptive Advisors, Pivotal bioVenture Partners, Rock Springs Capital and all existing investors Funding to Accelerate the Development of Targeted Alpha Therapeutics Across Multiple Cancer Types Based on Fusion’s Fast-Clear™ Linker Technology Platform Fusion Pharmaceuticals, a clinical-stage biopharmaceutical…